Cost-effectiveness of general practitioner- versus surgeon-led colon cancer survivorship care: an economic evaluation alongside a randomised controlled trial.
Cancer survivors
Colon cancer
Cost–benefit analysis
Primary health care
Quality of healthcare
Journal
Journal of cancer survivorship : research and practice
ISSN: 1932-2267
Titre abrégé: J Cancer Surviv
Pays: United States
ID NLM: 101307557
Informations de publication
Date de publication:
25 Apr 2023
25 Apr 2023
Historique:
received:
09
02
2023
accepted:
11
04
2023
medline:
25
4
2023
pubmed:
25
4
2023
entrez:
25
4
2023
Statut:
aheadofprint
Résumé
The aim of this study is to assess cost-effectiveness of general practitioner (GP) versus surgeon-led colon cancer survivorship care from a societal perspective. We performed an economic evaluation alongside the I CARE study, which included 303 cancer patients (stages I-III) who were randomised to survivorship care by a GP or surgeon. Questionnaires were administered at baseline, 3-, 6-, 12-, 24- and 36-months. Costs included healthcare costs (measured by iMTA MCQ) and lost productivity costs (SF-HLQ). Disease-specific quality of life (QoL) was measured using EORTC QLQ-C30 summary score and general QoL using EQ-5D-3L quality-adjusted life years (QALYs). Missing data were imputed. Incremental cost-effectiveness ratios (ICERs) were calculated to relate costs to effects on QoL. Statistical uncertainty was estimated using bootstrapping. Total societal costs of GP-led care were significantly lower compared to surgeon-led care (mean difference of - €3895; 95% CI - €6113; - €1712). Lost productivity was the main contributor to the difference in societal costs (- €3305; 95% CI - €5028; - €1739). The difference in QLQ-C30 summary score over time between groups was 1.33 (95% CI - 0.049; 3.15). The ICER for QLQ-C30 was - 2073, indicating that GP-led care is dominant over surgeon-led care. The difference in QALYs was - 0.021 (95% CI - 0.083; 0.040) resulting in an ICER of 129,164. GP-led care is likely to be cost-effective for disease-specific QoL, but not for general QoL. With a growing number of cancer survivors, GP-led survivorship care could help to alleviate some of the burden on more expensive secondary healthcare services.
Identifiants
pubmed: 37097550
doi: 10.1007/s11764-023-01383-4
pii: 10.1007/s11764-023-01383-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : KWF Kankerbestrijding/Stichting Alpe d'HuZes
ID : BMA 5954
Informations de copyright
© 2023. The Author(s).
Références
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
doi: 10.1136/gutjnl-2015-310912
pubmed: 26818619
Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2006.
Qaderi SM, Dickman PW, de Wilt JHW, Verhoeven RHA. Conditional survival and cure of patients with colon or rectal cancer: a population-based study. J Natl Compr Canc Netw. 2020;18(9):1230–7.
doi: 10.6004/jnccn.2020.7568
pubmed: 32886900
The Dutch Ministry of Health, Welfare and Sports (VWS) [Internet]. Accessed 11th of May 2022. [Available from: https://www.vzinfo.nl/dikkedarmkanker/zorguitgaven ].
Hakkaart-van Roijen L, Van der Linden N, Bouwmans CAM, et al. Costing manual: methodology of costing research and reference prices for economic evaluations in healthcare. Diemen: Dutch Healthcare Institute; 2016.
Brandenbarg D, Roorda C, Groenhof F, Havenga K, Berger MY, de Bock GH, et al. Increased primary health care use in the first year after colorectal cancer diagnosis. Scand J Prim Health Care. 2014;32(2):55–61.
doi: 10.3109/02813432.2014.929811
pubmed: 24931639
pmcid: 4075017
Heins M, Schellevis F, Rijken M, van der Hoek L, Korevaar J. Determinants of increased primary health care use in cancer survivors. J Clin Oncol. 2012;30(33):4155–60.
doi: 10.1200/JCO.2012.41.9101
pubmed: 23071230
Emery JD, Shaw K, Williams B, Mazza D, Fallon-Ferguson J, Varlow M, et al. The role of primary care in early detection and follow-up of cancer. Nat Rev Clin Oncol. 2014;11(1):38–48.
doi: 10.1038/nrclinonc.2013.212
pubmed: 24247164
Health Council of the Netherlands. Follow-up in oncology—identify objectives, substantiate actions. 2007; publication no. 2007/10.
Noteboom EA, Perfors IA, May AM, Stegmann ME, Duijts SF, Visserman EA, et al. GP involvement after a cancer diagnosis; patients’ call to improve decision support. BJGP Open. 2021;5(1):bjgpopen20X101124.
doi: 10.3399/bjgpopen20X101124
pubmed: 33172850
Vos JAM, Wieldraaijer T, van Weert H, van Asselt KM. Survivorship care for cancer patients in primary versus secondary care: a systematic review. J Cancer Surviv. 2020;15(1):66–76.
doi: 10.1007/s11764-020-00911-w
pubmed: 32815087
pmcid: 7822798
Hoeg BL, Bidstrup PE, Karlsen RV, Friberg AS, Albieri V, Dalton SO, et al. Follow-up strategies following completion of primary cancer treatment in adult cancer survivors. Cochrane Database Syst Rev. 2019;2019(11):425.
Duineveld LA, Wieldraaijer T, van Asselt KM, Nugteren IC, Donkervoort SC, van de Ven AW, et al. Improving care after colon cancer treatment in The Netherlands, personalised care to enhance quality of life (I CARE study): study protocol for a randomised controlled trial. Trials. 2015;16:284.
doi: 10.1186/s13063-015-0798-7
pubmed: 26112050
pmcid: 4499213
Vos JAM, Duineveld LAM, Wieldraaijer T, Wind J, Busschers WB, Sert E, et al. Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE): an interim analysis of 1-year results of a randomised, controlled trial. Lancet Oncol. 2021;22(8):1175–87.
doi: 10.1016/S1470-2045(21)00273-4
pubmed: 34224671
Jefford M, Howell D, Li Q, Lisy K, Maher J, Alfano CM, et al. Improved models of care for cancer survivors. The Lancet. 2022;399(10334):1551–60.
doi: 10.1016/S0140-6736(22)00306-3
Duineveld LAM, Vos JAM, Wieldraaijer T, Donkervoort SC, Wind J, van Weert H, et al. Recruitment challenges to the I CARE study: a randomised trial on general practitioner-led colon cancer survivorship care. BMJ Open. 2021;11(8): e048985.
doi: 10.1136/bmjopen-2021-048985
pubmed: 34429313
pmcid: 8386209
National Guideline Colorectal Carcinoma (CRC) [Internet]. Available from: https://www.oncoline.nl/colorectaalcarcinoom [Accessed 10th of June 2020].
Castor EDC. Castor Electronic Data Capture 2019 [Internet]. Available from: https://www.castoredc.com [Accessed 27th of August 2019].
Qaderi SM, Galjart B, Verhoef C, Slooter GD, Koopman M, Verhoeven RHA, et al. Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. Int J Colorectal Dis. 2021;36(11):2399–410.
doi: 10.1007/s00384-021-03914-w
pubmed: 33813606
pmcid: 8505312
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
doi: 10.1093/jnci/85.5.365
pubmed: 8433390
Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.
doi: 10.1016/0168-8510(96)00822-6
pubmed: 10158943
Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79–88.
doi: 10.1016/j.jclinepi.2015.08.007
pubmed: 26327487
Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff. Ned Tijdschr Geneeskd. 2005;149(28):1574–8.
pubmed: 16038162
iMTA Productivity and Health Research Group. Manual iMTA Medical Cost Questionnaire (iMCQ) [Internet]. Available from: https://www.imta.nl/questionnaires/imcq/publications/ [Accessed 15th of May 2022].
The Dutch Ministry of Health, Welfare and Sports (VWS) - Dutch Healthcare Institute [Internet]. Available from: https://www.medicijnkosten.nl/zoeken [Accessed 18th of May 2022].
van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. Int J Technol Assess Health Care. 1996;12(3):405–15.
doi: 10.1017/S0266462300009764
pubmed: 8840661
van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. 2011. J Stat Softw. 2011;45(3):67.
doi: 10.18637/jss.v045.i03
Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157–70.
doi: 10.1007/s40273-014-0193-3
pubmed: 25069632
pmcid: 4244574
White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–99.
doi: 10.1002/sim.4067
pubmed: 21225900
Rubin DB. Multiple imputation for nonresponse in surveys. Wiley, New York; 1987. p. xxix, 258.
El Alili M, van Dongen JM, Goldfeld KS, Heymans MW, van Tulder MW, Bosmans JE. Taking the analysis of trial-based economic evaluations to the next level: the importance of accounting for clustering. Pharmacoeconomics. 2020;38(11):1247–61.
doi: 10.1007/s40273-020-00946-y
pubmed: 32729091
pmcid: 7546992
Twisk JW. Applied multilevel analysis: a practical guide for medical researchers. Cambridge University Press; 2006.
doi: 10.1017/CBO9780511610806
Twisk JW. Applied longitudinal data analysis for epidemiology: a practical guide. Cambridge University Press; 2013.
doi: 10.1017/CBO9781139342834
Twisk JW. Analysis of data from randomized controlled trials. A practical guide Cham. Springer; 2021.
doi: 10.1007/978-3-030-81865-4
Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005;14(5):487–96.
doi: 10.1002/hec.944
pubmed: 15497198
Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ. 2004;13(5):405–15.
doi: 10.1002/hec.903
pubmed: 15127421
Hoch JS, Dewa CS. Advantages of the net benefit regression framework for economic evaluations of interventions in the workplace: a case study of the cost-effectiveness of a collaborative mental health care program for people receiving short-term disability benefits for psychiatric disorders. J Occup Environ Med. 2014;56(4):441–5.
doi: 10.1097/JOM.0000000000000130
pubmed: 24662952
Karpenko AW, Geenen JW, Vreman RA, Hovels A. The introduction of a threshold for the icer and the implications for reimbursement of drugs in the Dutch healthcare system. Value in Health. 2017;20(9):A671.
doi: 10.1016/j.jval.2017.08.1645
Augestad KM, Norum J, Dehof S, Aspevik R, Ringberg U, Nestvold T, et al. Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial. BMJ Open. 2013;3(4):e002391.
doi: 10.1136/bmjopen-2012-002391
pubmed: 23564936
pmcid: 3641467
Grunfeld E, Gray A, Mant D, Yudkin P, Adewuyi-Dalton R, Coyle D, et al. Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation. Br J Cancer. 1999;79(7–8):1227–33.
doi: 10.1038/sj.bjc.6690197
pubmed: 10098764
pmcid: 2362235
Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
doi: 10.1186/1477-7525-5-70
pubmed: 18154669
pmcid: 2248572
Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. Value Health. 2018;21(1):49–56.
doi: 10.1016/j.jval.2017.09.004
pubmed: 29304940
Vos JAM, de Best R, Duineveld LAM, van Weert HCPM, van Asselt KM. Delivering colon cancer survivorship care in primary care; a qualitative study on the experiences of general practitioners. BMC Primary Care. 2022;23(1):13.
doi: 10.1186/s12875-021-01610-w
pubmed: 35172743
pmcid: 8761520
Vos JA, van Miltenburg VE, Beverdam FH, van Weert HC, van Asselt KM. Patient experiences of GP-led colon cancer survivorship care: a Dutch mixed-methods evaluation. Br J Gen Pract. 2023;73(727):e115–23.
doi: 10.3399/BJGP.2022.0104
pubmed: 36316164
Vos JAM, Sert E, Busschers WB, Duineveld LAM, Wieldraaijer T, Wind J, et al. Detection of colon cancer recurrences during follow-up care by general practitioners versus surgeons. J Natl Cancer Inst. 2023. https://doi.org/10.1093/jnci/djad019
Wattchow DA, Weller DP, Esterman A, Pilotto LS, McGorm K, Hammett Z, et al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer. 2006;94(8):1116–21.
doi: 10.1038/sj.bjc.6603052
pubmed: 16622437
pmcid: 2361245